46. 悪性関節リウマチ Malignant rheumatoid arthritis Clinical trials / Disease details
臨床試験数 : 4,325 / 薬物数 : 2,671 - (DrugBank : 417) / 標的遺伝子数 : 187 - 標的パスウェイ数 : 224
Showing 1 to 10 of 49 diseases
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03938701 (ClinicalTrials.gov) | January 2022 | 25/2/2019 | Fluorescence Imaging of Disease Activity in IBD and Rheumatoid Arthritis Using OTL38 | Fluorescence Imaging for the Evaluation of Disease Activity in IBD and Rheumatoid Arthritis Using the Fluorescent Tracer OTL38 Targeting the Folate ß Receptor: a Single-center Pilot Study Fluorescence Imaging for the Evaluation of Disease Activity in IBD and Rheumatoid Arthritis Using th ... | IBD;Rheumatoid Arthritis | Drug: OTL38;Device: Fluorescence Imaging | University Medical Center Groningen | GlaxoSmithKline;On Target Laboratories, LLC;VU University Medical Center | Not yet recruiting | 18 Years | N/A | All | 30 | Phase 1 | Netherlands |
| 2 | ChiCTR2100042659 | 2021-01-25 | 2021-01-25 | Observation on the clinical effect of treating rheumatoid arthritis based on the theory of kidney deficiency and cold coagulation Observation on the clinical effect of treating rheumatoid arthritis based on the theory of kidney de ... | Observation on the clinical effect of treating rheumatoid arthritis based on the theory of kidney deficiency and cold coagulation Observation on the clinical effect of treating rheumatoid arthritis based on the theory of kidney de ... | Rheumatoid Arthritis | experimental group:Fuzi Guizhi Decoction granules+Methotrexate tablets + Folic acid tablets;control group:Methotrexate tablets + Folic acid tablets; experimental group:Fuzi Guizhi Decoction granules+Methotrexatetablets + Folic acidtablets;control gr ... | The Affiliated Hospital of Yunnan University of Traditional Chinese Medicine | NULL | Recruiting | 18 | 65 | Both | experimental group:36;control group:36; | China | |
| 3 | ChiCTR2100042440 | 2021-01-21 | 2021-01-21 | Observation on Qingre Tongluo recipe in the treatment of difficult-to-treat rheumatoid arthritis with heat syndrome and its effect on drug resistance gene Observation on Qingre Tongluo recipe in the treatment of difficult-to-treat rheumatoid arthritis wit ... | Observation on Qingre Tongluo recipe in the treatment of difficult-to-treat rheumatoid arthritis with heat syndrome and its effect on drug resistance gene Observation on Qingre Tongluo recipe in the treatment of difficult-to-treat rheumatoid arthritis wit ... | difficult-to-treat rheumatoid arthritis | The normal group:No special treatment; Primary untreated group:Do not give any treatment, only before treatment for blood, the group does not consider follow-up treatment, recommended patients to seek medical advice, follow the doctor 's orders;Therapeutic effective group:Continue the original treatment plan;Refractory (trial group):Methotrexate + folic acid tablets + Adalimumab + Qingre Tongluo Prescription;Refractory (control group):Methotrexate + folic acid tablets + adalimumab + simulant; The normal group:No special treatment; Primary untreated group:Do not give any treatment, only befor ... | Yunnan Hospital of Traditional Chinese Medicine/The First Affiliated Hospital of Yunnan University of traditional Chinese Medicine Yunnan Hospital of Traditional Chinese Medicine/The First Affiliated Hospital of Yunnan University o ... | NULL | Recruiting | 18 | 70 | Both | The normal group:15; Primary untreated group:15;Therapeutic effective group:15;Refractory (trial group):15;Refractory (control group):15; | China | |
| 4 | ChiCTR2100042328 | 2021-01-19 | 2021-01-19 | Effect of Wenyang Tongluo Recipe on Cold Syndrome of Rheumatoid Arthritis and Drug Resistant Gene | Effect of Wenyang Tongluo Recipe on Cold Syndrome of Rheumatoid Arthritis and Drug Resistant Gene | Rheumatoid arthritis | The normal group:No special treatment will be given;Primary untreated group:No treatment was given, only blood was drawn before treatment, and follow-up treatment was not considered in this group. Patients were advised to seek medical treatment by themselves and follow the doctor's advice;Therapeutic effective group:Continue with the original regimen;Observation group:Methotrexate + folic acid tablets + Adamumab + Wenyang Tongluo Recipient;The control group:Methotrexate + folic acid tablets + adamulizumab + simulation agent; The normal group:No special treatment will be given;Primary untreated group:No treatment was given, ... | Yunnan Hospital of Traditional Chinese Medicine (The First Affiliated Hospital of Yunnan University of Traditional Chinese Medicine) Yunnan Hospital of Traditional Chinese Medicine (The First Affiliated Hospital of Yunnan University ... | NULL | Recruiting | 18 | 70 | Both | The normal group:15;Primary untreated group:15;Therapeutic effective group:15;Observation group:15;The control group:15; | China | |
| 5 | ChiCTR2100041819 | 2021-01-01 | 2021-01-06 | Clinical study of Hanbi ointment in the treatment of rheumatoid arthritis | Clinical study of Hanbi ointment in the treatment of rheumatoid arthritis | Rheumatoid arthritis | Treatment group:Hanbi ointment + Methotrexate + Leflunomide Tablets + Folic Acid Tablets ;control group:Hanbi ointment simulant+ Methotrexate + Leflunomide Tablets + Folic Acid Tablets ; Treatment group:Hanbi ointment + Methotrexate+ LeflunomideTablets + Folic AcidTablets ;control group ... | The First Affiliated Hospital of Yunnan University of traditional Chinese Medicine | NULL | Recruiting | Both | Treatment group:36;control group:36; | China | |||
| 6 | ChiCTR2100041821 | 2021-01-01 | 2021-01-06 | Observation on the clinical curative effect of external application of Rebi ointment in treating rheumatoid arthritis (damp-heat syndrome) joint pain Observation on the clinical curative effect of external application of Rebi ointment in treating rhe ... | Observation on the clinical curative effect of external application of Rebi ointment in treating rheumatoid arthritis (damp-heat syndrome) joint pain Observation on the clinical curative effect of external application of Rebi ointment in treating rhe ... | Rheumatoid Arthritis | therapy group:Rebi ointment, Methotrexate tablets, Leflunomide tablets, and Folic acid tablets ;Control group:Rebi cream simulant, Methotrexate tablets, Leflunomide tablets, and Folic acid tablets; therapy group:Rebi ointment, Methotrexatetablets, Leflunomidetablets, and Folic acidtablets ;Control ... | Yunnan Provincial Hospital of Traditional Chinese Medicine/The First Affiliated Hospital of Yunnan University of Traditional Chinese Medicine Yunnan Provincial Hospital of Traditional Chinese Medicine/The First Affiliated Hospital of Yunnan U ... | NULL | Recruiting | 18 | 70 | Both | therapy group:36;Control group:36; | China | |
| 7 | ChiCTR2100041894 | 2021-01-01 | 2021-01-09 | Observation on the clinical effect of external application of Yi medicine SISE ointment in the treatment of rheumatoid arthritis (wind cold dampness syndrome) joint swelling and pain Observation on the clinical effect of external application of Yi medicine SISE ointment in the treat ... | Observation on the clinical effect of external application of Yi medicine SISE ointment in the treatment of rheumatoid arthritis (wind cold dampness syndrome) joint swelling and pain Observation on the clinical effect of external application of Yi medicine SISE ointment in the treat ... | Rheumatoid arthritis | therapy group:Yiyisise ointment, Methotrexate, Leflunomide tablets and Folic acid tablets ;Control group:Yiyisise ointment simulant, Methotrexate, Leflunomide tablets and Folic acid tablets; therapy group:Yiyisise ointment, Methotrexate, Leflunomidetablets and Folic acidtablets ;Control gro ... | Yunnan Hospital of Traditional Chinese Medicine | NULL | Recruiting | Both | therapy group:36;Control group:36; | China | |||
| 8 | JPRN-jRCT1041190125 | 09/03/2020 | 09/03/2020 | PRECIOUS-B study | Patient REported, Clinical, and Imaging OUtcomes of tapering methotrexate in patients with rheumatoid arthritis in Stable low disease activity with Baricitinib - PRECIOUS-B study Patient REported, Clinical, and Imaging OUtcomes of tapering methotrexate in patients with rheumatoi ... | Rheumatoid arthritis | 1) MTX* Week 0 to 12 - Reduced after registration. - The dosing frequency of MTX is decreased from weekly to biweekly without a change in dose, regardless of the initial dose. - The dosing frequency of folic acid is decreased from weekly to biweekly without a change in dose if concomitantly used. Week 12 to 52 - Discontinued if low disease activity was maintained. - Folic acid is discontinued if concomitantly used. *The allowable range of adherence is -20% to +20%. 2) BAR - Continued at a stable dose and interval throughout the course of the study. 3) csDMARDs other than MTX - Continued at a stable dose and interval throughout the course of the study. 4) Glucocorticoids - Continued at a stable dose up to week 36, and allowed to taper after week 36. 5) Rescue treatments One or more of the following rescue treatments are performed if the CDAI score was >10 and at the discretion of the investigator and/or upon patient request - Changing the dosing frequency back to weekly administration, restarting, or increasing doses of MTX. - Increasing doses of or adding csDMARDs other than MTX. - Increasing doses of or adding glucocorticoids. - Drainage of synovial fluid. - Administering an intraarticular injection of corticosteroids, hyaluronic acid, or lidocaine. 1) MTX* Week 0 to 12 - Reduced after registration. - The dosing frequency of MTXis decreased from weekl ... | Takahashi Nobunori | NULL | Recruiting | >= 20age old | Not applicable | Both | 51 | N/A | Japan |
| 9 | EUCTR2018-004429-94-NL (EUCTR) | 21/01/2020 | 17/06/2019 | Monitoring of respons to therapy in rheumatoid arthritis with the help of a PET scan. | [18F]PEG-folate PET-CT imaging for monitoring of therapy response in rheumatoid arthritis patients | Rheumatoid Arthritis;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] | Product Name: [18F]PEG-Folate | VU Medical Center, department of Rheumatology | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 10 | Phase 4 | Netherlands | ||
| 10 | EUCTR2018-004287-56-FR (EUCTR) | 21/11/2019 | 31/01/2020 | Methotrexate and Metformin in rheumatoid arthritis patients | Randomized placebo-controlled trial comparing Methotrexate vs. Methotrexate/Metformin association in rheumatoid arthritis patients: METorMET² study - METorMET2 Randomized placebo-controlled trial comparing Methotrexate vs. Methotrexate/Metformin association in ... | rheumatoid arthritis (RA) MedDRA version: 20.0;Level: HLT;Classification code 10039075;Term: Rheumatoid arthritis and associated conditions;System Organ Class: 100000004870 ;Therapeutic area: Body processes [G] - Immune system processes [G12] rheumatoid arthritis (RA) MedDRA version: 20.0;Level: HLT;Classification code 10039075;Term: Rheumat ... | Trade Name: METFORMINE ARROW 500mg Product Name: Metformin Trade Name: Methotrexate Product Name: Methotrexate Trade Name: Methotrexate Product Name: Methotrexate Trade Name: Acide folique Product Name: Acide folique Product Code: B03BB01 Trade Name: Prednisone Product Name: Prednisone Product Code: H02AB07 Trade Name: METFORMINEARROW 500mg Product Name: Metformin Trade Name: Methotrexate Product Name: Methot ... | CHU de Bordeaux | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 128 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - ( ... | France |